

Search details for Pubmed

(("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields]) AND ("COVID-19"[All Fields] OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2"[All Fields] OR "2019-nCoV"[All Fields] OR "SARS-CoV-2"[All Fields] OR "2019nCoV"[All Fields] OR ("Wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND 2019/12[PDAT] : 2030[PDAT])) AND ("severe acute respiratory syndrome coronavirus 2"[Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2"[All Fields] OR "sars cov 2"[All Fields])) OR (novel[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields]))

FIGURE LEGEND

eFigure 1. Pooled prevalence of anorexia in COVID-19 patients

Abbreviations: COVID-19, coronavirus disease 2019

eFigure 2. Pooled prevalence of nausea/vomiting in COVID-19 patients

Abbreviations: COVID-19, coronavirus disease 2019

eFigure 3. Pooled prevalence of diarrhoea in COVID-19 patients

Abbreviations: COVID-19, coronavirus disease 2019

eFigure 4. Pooled prevalence of abdominal pain/discomfort in COVID-19 patients

Abbreviations: COVID-19, coronavirus disease 2019

eFigure 5. Pooled stool viral RNA positivity rate in COVID-19 patients

Abbreviations: COVID-19, coronavirus disease 2019

eFigure 6. Pooled persistent stool viral RNA positivity rate in COVID-19 patients with subsequent viral clearance in respiratory specimens


Abbreviations: COVID-19, coronavirus disease 2019

eTable 1. Comparison of gastrointestinal symptoms according to COVID-19 severity

Study	Disease severity	All gastrointestinal symptoms	Anorexia	Nausea/vomiting	Diarrhoea	Abdominal pain/discomfort
Guan W et al ¹	Severe (n=173)	≥12 (6.9%)	n.a.	12 (6.9%)	10 (5.8%)	n.a.
	Non-severe (n=926)	≥43 (4.6%)	n.a.	43 (4.6%)	32 (3.5%)	n.a.
Fang D et al ²	Severe	17/20 (85.0%)	n.a.	n.a.	17/38 (44.7%)	n.a.
	Non-severe	142/181 (78.5%)	n.a.	n.a.	129/257 (50.2%)	n.a.
Zhou F ³	Non-survivor (n=54)	≥3 (5.6%)	n.a.	3 (5.6%)	2 (3.7%)	n.a.
	Survivor (n=137)	≥7 (5.1%)	n.a.	4 (2.9%)	7 (5.1%)	n.a.
Zhang JJ et al ⁴	Severe (n=57)	24 (42.1%)	8 (14.0%)	Vomiting: 2 (3.5%) Nausea: 5 (8.8%)	9 (19.8%)	6 (10.5%)
	Non-severe (n=82)	31 (37.8%)	9 (11.0%)	Vomiting: 5 (6.1%) Nausea: 19 (23.2%)	9 (11.0%)	2 (2.4%)
Wang D et al ⁵	ICU (n=36)	≥24 (66.7%)	24 (66.7%)	Nausea: 4 (11.1%) Vomiting: 3 (8.3%)	6 (16.7%)	3 (8.3%)
	Non-ICU (n=102)	≥31 (30.4%)	31 (30.4%)	Nausea: 10 (9.8%) Vomiting: 2 (2.0%)	8 (7.8%)	0 (0)
Peng YD ⁶	ICU (n=16)	2 (12.5%)	n.a.	n.a.	2 (12.5%)	n.a.
	Non-ICU (n=96)	13 (13.5%)	n.a.	n.a.	13 (13.5%)	n.a.
Li K et al ⁷	Severe (n=25)	2 (8.0%)	n.a.	n.a.	2 (8.0%)	
	Non-severe (n=58)	5 (8.6%)	n.a.	n.a.	5 (8.6%)	
Fang X et al ⁸	Severe (n=24)	≥3 (12.5%)	2 (8.3%)	n.a.	3 (12.5%)	n.a.
	Non-severe (n=55)	≥3 (5.5%)	3 (5.5%)	n.a.	1 (1.8%)	n.a.
Yang X et al ⁹	ICU non-survivors (n=32)	1 (3.1%)	n.a.	Vomiting: 1 (3.1%)	n.a.	n.a.
	ICU survivors (n=20)	1 (5.0%)	n.a.	Vomiting: 1 (5.0%)	n.a.	n.a.
Xu YH et al ¹⁰	Severe (n=13)	0	n.a.	n.a.	n.a.	n.a.
	Non-severe (n=37)	1 (2.7%)	n.a.	n.a.	n.a.	n.a.
Huang C et al ¹¹	ICU (n=13)	0	n.a.	n.a.	0	n.a.
	Non-ICU (n=28)	1/25 (4.0%)	n.a.	n.a.	1/25 (4.0%)	n.a.


Abbreviations: COVID-19, coronavirus disease 2019; intensive care unit; n.a. not available

eFigure 1. Pooled prevalence of anorexia in COVID-19 patients




Abbreviations: COVID-19, coronavirus disease 2019

eFigure 2. Pooled prevalence of nausea/vomiting in COVID-19 patients




Abbreviations: COVID-19, coronavirus disease 2019

eFigure 3. Pooled prevalence of diarrhea in COVID-19 patients




Abbreviations: COVID-19, coronavirus disease 2019

eFigure 4. Pooled prevalence of abdominal pain/discomfort in COVID-19 patients




Abbreviations: COVID-19, coronavirus disease 2019

eFigure 5. Pooled stool viral RNA positivity rate in COVID-19 patients



Abbreviations: COVID-19, coronavirus disease 2019

eFigure 6. Pooled persistent stool viral RNA positivity rate in COVID-19 patients with subsequent viral clearance in respiratory specimens



Abbreviations: COVID-19, coronavirus disease 2019

References

1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020 [epub ahead of print].
2. Fang D, Ma JD, Guan JL, et al. Manifestations of digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan, China: a single-center, descriptive study. *Chin J Dig* 2020;40(3).
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020 [epub ahead of print].
4. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020;0:1-12.
5. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020;323:1061-69.
6. Peng YD, Meng K, Guan HQ, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. *Zhonghua Xin Xue Guan Bing Za Zhi* 2020;48:E004.
7. Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia. *Invest Radiol* 2020 [epub ahead of print].
8. Fang X, Mei Q, Yang T, et al. Clinical characteristics and treatment strategies of 79 patients with COVID-19. *Chin Pharm Bulletin* 2020;36(4):1-7.
9. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020 [epub ahead of print].

10. Xu YH, Dong JH, An WM, et al. Clinical and computed tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2. *J Infect* 2020 [epub ahead of print].
11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.